Status:
TERMINATED
Protein Supplementation in Dialysis Patients
Lead Sponsor:
Vanderbilt University
Conditions:
End Stage Renal Disease
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The mortality rate in chronic hemodialysis (CHD) patients remains excessively high and approaches 21% per year. Among the many factors that adversely affects patient outcome is uremic malnutrition, a ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- On hemodialysis for more than 3 months, on a thrice weekly hemodialysis program.
- Adequately dialyzed (Kt/V \> 1.2).
- Age 18-75
- Exclusion criteria:
- Pregnant women.
- Severe unstable underlying disease besides commonly associated with end stage renal disease. Cardiac patients that are stable will be included.
- Patients hospitalized within the last month prior to the study.
- Patients with malfunctioning arterial-venous access \[recirculation and/or blood flow \< 500 ml/min for an arterial-venous graft (AVG) or \<400 ml/min for an arterial-venous fistula (AVF)\] Patients receiving steroids and/or other immunosuppressive agents.
Exclusion
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2007
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00367198
Start Date
August 1 2006
End Date
November 1 2007
Last Update
July 12 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232